We would like to inform you that we have completed the first part of the study with a single, escalating dose (FIH, SAD) (Part A), of the innovative antidiabetic drug.

 

We would like to inform you that we have completed the first part of the study with a single, escalating dose (FIH, SAD) (Part A), of the innovative antidiabetic drug. The project was implemented in cooperation with a Polish pharmaceutical company. The new therapy aims to reduce insulin resistance and to regulate the chronic high blood glucose level. Due to the state of the pandemic, the study was conducted in accordance with the highest sanitary standards as well as procedures related to the monitoring of the epidemic state. This approach, combined with the principles of GCP, ensured the safety and well-being of our patients. Soon we are starting the second part of the study (hello B0) with multiple, escalating dose of the new drug.

Go back

News

BRG team participated in BIO-Europe®

On 26th -27th  of October BRG team participated in BIO-Europe® the largest partnering conference in Europe dedicated to the global biotechnology industry. 

Read more …

BRG Team participated in the official opening of the Celon Pharma Research and Development Center

On September 28, 2020 BRG Team participated in the official opening of the Celon Pharma Research and Development Center

Read more …

Dr Jarosław Długołęcki

We are pleased to welcome a new member of the BRG medical expert team. Mr Jarosław Długołęcki, (M.D.) - doctor with extensive knowledge and 16-years’ experience in clinical studies at the international level.

Read more …

Badania kliniczne faz wczesnych szczepionek – wyzwania w obliczu nowych zagrożeń

Szczepienia ochronne niezaprzeczalnie należą do jednych z najbardziej przełomowych odkryć nowoczesnej medycyny.

Read more …

About Us | Services | Our Site | Partners | Smoking Risk Study | Contact Us

Early Phase Clinical Trials

2022 © Bio Research Group. All rights reserved.

 

scroll to top ▲